Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Evaluation of MRD negativity in patients with relapsed or refractory multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
7 Dec 2020
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma
Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma ( Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma ( Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA )
7 Dec 2020
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in ne...
Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )
7 Dec 2020
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelph...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Trea...
Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )
7 Dec 2020
Predictive factors for overall survival in chronic myeloid leukaemia patients: a...
Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy
Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )
6 Dec 2020
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potent...
Prof David Teachey - The University of Pennsylvania, Rutledge, USA
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL ( Prof David Teachey - The University of Pennsylvania, Rutledge, USA )
6 Dec 2020
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukae...
Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )
5 Dec 2020
ecancer special issue on immunotherapy
Dr Nicola Fusco and Elham Sajjadi - European Institute of Oncology, Milan, Italy
ecancer special issue on immunotherapy ( Dr Nicola Fusco and Elham Sajjadi - European Institute of Oncology, Milan, Italy )
3 Dec 2020
PARP inhibitors in prostate cancer: A promise delivered
Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA
PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )
1 Dec 2020